Are the biggest Aim stocks also the best: Companies and Markets Show
This week, we return to our ultimate guide to Britain’s junior market, as we mark the release of Part Two of our Aim 100 Special Report. We kick off with medical technology business Niox, which has just completed that relatively rare thing: a tender offer to shareholders. Julian Hofmann investigates whether the…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like Investors' Chronicle →
This is what needs to happen for UK smaller company shares to bounce back
Investment Trust Show: can big dividends make up for weak share price performance? The challenges facing renewable energy and infrastructure trusts.
Is the FTSE 100 finally having its moment in the sun?
Q2 Portfolio Review: Winners, Losers & What We're Buying
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.